Fintel reports that on March 7, 2025, Stifel downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy to Hold. Analyst Price Forecast Suggests 858.65% Upside As of March 4, 2025, the ...

A Former Bradley basketball star was inducted into the Missouri Valley Conference Hall of Fame on Friday. Peoria Friendship ...

Daryl Hall has announced a new stretch of US tour dates going down in the summer of 2025 with Squeeze frontman Glen Tilbrook ...

While consumers shied away from other retailers in what turned out to be a colder-than-normal month, Costco customers still showed up in force in February as U.S. core comparable-store sales jumped ...

Neumora Therapeutics (NASDAQ:NMRA) stock drops 11% as Stifel downgrades nothing that J&J (JNJ) discontinues a drug similar to NMRA's lead asset. Read more here.

In a report released today, Mark Astrachan from Stifel Nicolaus maintained a Buy rating on Costco (COST – Research Report), with a price target ...

Stifel downgraded Neumora Therapeutics (NMRA) to Hold from Buy with a price target of $2, down from $6. The shares are now “much harder to ...

Shares in Italian luxury fashion firm Salvatore Ferragamo tumbled as the company continues to struggle with a brand revamp ...

Mutual of America Capital Management LLC reduced its holdings in GXO Logistics, Inc. (NYSE:GXO – Free Report) by 2.2% during ...